Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
NCT07246031Phase 2Recruiting
- Sponsor
- Bio-Phoenix
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inolimomab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Bio-Phoenix. Primary endpoints: Incidence of Grades II-IV acute Graft-Versus-Host Disease at Day 100, Adverse Events at 1 year and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
inolimomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07246031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246031.